Go Pro
OTCMKTS:CVSI

CV Sciences (CVSI) Stock Price, News & Analysis

CV Sciences logo
$0.02 0.00 (-6.53%)
As of 08/24/2026 03:51 PM Eastern

About CV Sciences Stock (OTCMKTS:CVSI)

Advanced

Key Stats

Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.10
Volume
443,657 shs
Average Volume
383,320 shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CV Sciences, Inc. is a developer, manufacturer and marketer of hemp-derived products, with a focus on cannabidiol (CBD) formulations for both consumer and industrial applications. The company’s consumer segment offers a range of dietary supplements, topical creams, personal care items and pet products under its flagship PlusCBD™ Oil brand, while its industrial segment provides hemp-derived ingredients for use in wellness, pharmaceutical and cosmetic formulations.

Headquartered in San Diego, California, CV Sciences operates a manufacturing facility in El Cajon that oversees cultivation partnerships, extraction, refinement and product formulation. The company sells its branded products through e-commerce channels, specialty retailers, pharmacies and major retail chains, and it holds regulatory registrations and quality certifications designed to meet evolving standards for hemp-derived products in domestic and select international markets.

Since its incorporation in Delaware in 2012, CV Sciences has expanded its geographic reach to serve customers across North America, Europe and parts of Asia, with strategic partnerships aimed at broadening distribution and ensuring supply-chain integrity. The company emphasizes scientific research, quality control and regulatory compliance, maintaining laboratory testing protocols for potency and purity at multiple stages of production.

CV Sciences is guided by a management team with experience in nutraceuticals, regulatory affairs and consumer-goods marketing. The company continues to invest in product innovation, clinical research collaborations and brand development as it seeks to strengthen its position in the growing hemp-derived CBD market.

AI Generated. May Contain Errors.

Receive CVSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CV Sciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVSI Stock News Headlines

CV Sciences Q2 Earnings Call Highlights
CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel
See More Headlines

CVSI Stock Analysis - Frequently Asked Questions

CV Sciences' stock was trading at $0.0614 at the start of the year. Since then, CVSI shares have decreased by 69.7% and is now trading at $0.0186.

CV Sciences, Inc. (OTCMKTS:CVSI) posted its earnings results on Thursday, August, 12th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $5.13 million for the quarter, compared to the consensus estimate of $5.12 million. CV Sciences had a negative net margin of 15.74% and a negative trailing twelve-month return on equity of 132.06%.

Shares of CVSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CV Sciences investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Charlotte's Web (CWBHF), Cronos Group (CRON), Kushco (KSHB), NVIDIA (NVDA) and Organigram Global (OGI).

Company Calendar

Last Earnings
8/12/2021
Today
8/24/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:CVSI
Previous Symbol
NASDAQ:CVSI
CIK
1510964
Employees
70
Year Founded
2016

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$960 thousand
Net Margins
-15.74%
Pretax Margin
-15.69%
Return on Equity
-132.06%
Return on Assets
-29.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.99
Quick Ratio
0.18

Sales & Book Value

Annual Sales
$13.79 million
Price / Sales
0.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.01 per share
Price / Book
1.86

Miscellaneous

Outstanding Shares
224,140,000
Free Float
209,119,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.47

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (OTCMKTS:CVSI) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners